Cargando…

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe

As per the EMA definition, adaptive pathways is a scientific concept for the development of medicines which seeks to facilitate patient access to promising medicines addressing high unmet need through a prospectively planned approach in a sustainable way. This review reports the findings of activiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouvy, Jacoline C., Sapede, Claudine, Garner, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881456/ https://www.ncbi.nlm.nih.gov/pubmed/29636692 http://dx.doi.org/10.3389/fphar.2018.00280

Ejemplares similares

Introduction of managed entry agreements in Korea: Problem, policy, and politics
por: Kim, Hyungmin, et al.
Publicado: (2023)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)

Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
por: Ciulla, Michele, et al.
Publicado: (2023)

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022)

Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)

All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2019)

The New and Old Europe: East-West Split in Pharmaceutical Spending
por: Jakovljevic, Mihajlo, et al.
Publicado: (2016)

Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies
por: Bouvy, Jacoline C., et al.
Publicado: (2015)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies
por: Garattini, Silvio, et al.
Publicado: (2021)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Editorial: Ethnopharmacology in Central and Eastern Europe in the Context of Global Research Developments
por: Tewari, Devesh, et al.
Publicado: (2019)

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014)

Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications from ESAC-Net and WHO Europe
por: Robertson, Jane, et al.
Publicado: (2021)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Medicines with one seller and many buyers: strategies to increase the power of the payer
por: Rintoul, Andrew, et al.
Publicado: (2020)

Corrigendum: Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications From ESAC-Net and WHO Europe
por: Robertson, Jane, et al.
Publicado: (2021)

An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe
por: Ebbers, Hans C., et al.
Publicado: (2015)

Stakeholder views of managed entry agreements: A literature review of national studies
por: Thanimalai, Subramaniam, et al.
Publicado: (2021)

Development of the Practice of Pharmaceutical Care for Cancer Pain Management in Outpatient Clinics Using the Delphi Method
por: Zhang, Lu, et al.
Publicado: (2022)

Considerations for Adapting Pre-existing Mechanistic Quantitative Systems Pharmacology Models for New Research Contexts
por: Weis, Michael, et al.
Publicado: (2019)

Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
por: Gleeson, Deborah, et al.
Publicado: (2019)

Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals
por: Gleeson, Deborah, et al.
Publicado: (2017)

Impact of a Collaborative Pharmaceutical Care Service for Patients With Parkinson’s Disease
por: Yi, Zhan-Miao, et al.
Publicado: (2022)

Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province
por: Matlala, Moliehi, et al.
Publicado: (2020)

Cost-benefit analysis of the integrated pharmaceutical supply chain information service after the establishment of the Korean Pharmaceutical Information Service
por: Kim, Myojeong, et al.
Publicado: (2022)

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
por: Salek, Sam M., et al.
Publicado: (2019)

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Physiological and Pharmaceutical Considerations for Rectal Drug Formulations
por: Hua, Susan
Publicado: (2019)

The Potential of Cryptophyte Algae in Biomedical and Pharmaceutical Applications
por: Abidizadegan, Maryam, et al.
Publicado: (2021)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Corporate social responsibility of pharmaceutical industry in Korea
por: Bae, Green, et al.
Publicado: (2022)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

Editorial: Protein nanoparticles: characterization and pharmaceutical application
por: Gagliardi, Agnese, et al.
Publicado: (2023)

Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis
por: Huang, Zhen-Dong, et al.
Publicado: (2020)

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
por: Efthymiadou, Olina, et al.
Publicado: (2022)

STIM and Orai1 Variants in Store-Operated Calcium Entry
por: Rosado, Juan A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qgki5frccml7lmg96kubrpha1d